The current 5-year CMT rate, referring to the 5-year survival rate after combined modality therapy for early-stage low-risk Hodgkin's Lymphoma, is reported to be high. Specifically, for patients with PET-2 negative results, the estimated 5-year progression-free survival (PFS) rate after CMT is 94.2%. This rate is significantly higher than the 86.7% PFS rate for patients treated with ABVD alone, indicating the efficacy of CMT in this patient population.
7 answers
Eleonora
Sun Nov 03 2024
The current 5 Year Treasury Rate stands at 4.11%.
Caterina
Sat Nov 02 2024
Last year, the 5 Year Treasury Rate was 4.80%.
SkylitEnchantment
Sat Nov 02 2024
This indicates a decline in the rate since the previous year.
isabella_oliver_musician
Sat Nov 02 2024
This figure matches the previous market day's rate.
Bianca
Sat Nov 02 2024
BTCC, a top cryptocurrency exchange, offers a range of services.